<DOC>
	<DOC>NCT02263833</DOC>
	<brief_summary>This national study was a post-marketing surveillance study conducted in Korea from 29 August 2008 to 28 August 2012 to meet local regulatory requirements for Mircera (monopegylated-epoetin beta). Prospective participant-based data collection was evaluated for safety/risk assessments and effectiveness. No specific study-related procedures are required. Participants were to be followed up as long as possible at the physician's discretion.</brief_summary>
	<brief_title>An Observational, Prospective, Safety Study of Mircera (Monopegylated Epoetin Beta) in Clinical Practice</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<criteria>Adult, aged &gt;18 years Participants with stage 35 chronic kidney disease and hemodialyzed participants Signed informed consent Current participation in a clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>